Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4724 ARTÍCULOS , VIENDO DEL 4276 AL 4290

Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson's disease

Bose A, Beal MF.

Eur J Neurosci. 2019 Feb;49(4):525-532. doi: 10.1111/ejn.14264. Epub 2018 Dec 1.

Unusual features of ependymoma in a patient with Parkinson's disease

Witton LA, Fong C, Reddy K, Provias J, Lu JQ.

J Clin Neurosci. 2019 Jan;59:310-312. doi: 10.1016/j.jocn.2018.10.124. Epub 2018 Nov 6.

Red flags phenotyping: A systematic review on clinical features in atypical parkinsonian disorders

Bhidayasiri R, Sringean J, Reich SG, Colosimo C.

Parkinsonism Relat Disord. 2019 Feb;59:82-92. doi: 10.1016/j.parkreldis.2018.10.009. Epub 2018 Oct 6.

Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients

Dragašević-Mišković N, Petrović I, Stanković I, Kostić VS.

Expert Opin Pharmacother. 2019 Feb;20(2):219-230. doi: 10.1080/14656566.2018.1543407. Epub 2018 Nov 9.

Post-translational modifications of Parkinson's disease-related proteins: Phosphorylation, SUMOylation and Ubiquitination

Junqueira SC, Centeno EGZ, Wilkinson KA, Cimarosti H.

Biochim Biophys Acta Mol Basis Dis. 2019 Aug 1;1865(8):2001-2007. doi: 10.1016/j.bbadis.2018.10.025. Epub 2018 Nov 6.

Mental health in Parkinson's disease after receiving aquatic therapy: a clinical trial

Pérez-de la Cruz S.

Acta Neurol Belg. 2019 Jun;119(2):193-200. doi: 10.1007/s13760-018-1034-5. Epub 2018 Nov 10.

Is the Munich dysphagia Test-Parkinson's disease (MDT-PD) a valid screening tool for patients at risk for aspiration?

Buhmann C, Flügel T, Bihler M, Gerloff C, Niessen A, Hidding U, Nienstedt JC, Pflug C.

Parkinsonism Relat Disord. 2019 Apr;61:138-143. doi: 10.1016/j.parkreldis.2018.10.031. Epub 2018 Nov 1.

Strategies for brain-targeting liposomal delivery of small hydrophobic molecules in the treatment of neurodegenerative diseases

Wang ZY, Sreenivasmurthy SG, Song JX, Liu JY, Li M.

Drug Discov Today. 2019 Feb;24(2):595-605. doi: 10.1016/j.drudis.2018.11.001. Epub 2018 Nov 8.

Microbial treatment: the potential application for Parkinson's disease

Fang X.

Neurol Sci. 2019 Jan;40(1):51-58. doi: 10.1007/s10072-018-3641-6. Epub 2018 Nov 10.

Neurotheranostics as personalized medicines

Kevadiya BD, Ottemann BM, Thomas MB, Mukadam I, Nigam S, McMillan J, Gorantla S, Bronich TK, Edagwa B, Gendelman HE.

Adv Drug Deliv Rev. 2019 Aug;148:252-289. doi: 10.1016/j.addr.2018.10.011. Epub 2018 Oct 26.

Enabling biomarker discovery in Parkinson's disease using multiomics: challenges, promise and the future

Kiebish MA, Narain NR.

Per Med. 2019 Jan;16(1):5-7. doi: 10.2217/pme-2018-0115. Epub 2018 Nov 13.

Effect of istradefylline on mood disorders in Parkinson's disease

Nagayama H, Kano O, Murakami H, Ono K, Hamada M, Toda T, Sengoku R, Shimo Y, Hattori N.

J Neurol Sci. 2019 Jan 15;396:78-83. doi: 10.1016/j.jns.2018.11.005. Epub 2018 Nov 5.

In vivo, in vitro and pharmacologic models of Parkinson's disease

Salari S, Bagheri M.

Physiol Res. 2019 Mar 6;68(1):17-24. doi: 10.33549/physiolres.933895. Epub 2018 Oct 23.

5-HT(2A) blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review

Kwan C, Frouni I, Bédard D, Nuara SG, Gourdon JC, Hamadjida A, Huot P.

Exp Brain Res. 2019 Feb;237(2):435-442. doi: 10.1007/s00221-018-5434-9. Epub 2018 Nov 15.

Charcot spinal arthropathy presenting as adjacent segment disease after lumbar spinal fusion surgery in Parkinson's disease: A case report

Miura K, Koda M, Tatsumura M, Shiina I, Mammoto T, Hirano A, Abe T, Funayama T, Noguchi H, Yamazaki M.

J Clin Neurosci. 2019 Mar;61:281-284. doi: 10.1016/j.jocn.2018.11.013. Epub 2018 Nov 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias